1 December 2023 false No description of principal activity Taxfiler 2024.6 11072275business:PrivateLimitedCompanyLtd2023-12-012024-11-30 110722752023-11-30 110722752023-12-012024-11-30 11072275business:AuditExemptWithAccountantsReport2023-12-012024-11-30 11072275business:FilletedAccounts2023-12-012024-11-30 110722752024-11-30 110722752023-11-30 11072275core:WithinOneYear2024-11-30 11072275core:WithinOneYear2023-11-30 11072275core:AfterOneYear2024-11-30 11072275core:AfterOneYear2023-11-30 11072275core:ShareCapitalcore:PreviouslyStatedAmount2024-11-30 11072275core:ShareCapitalcore:PreviouslyStatedAmount2023-11-30 11072275core:RetainedEarningsAccumulatedLossescore:PreviouslyStatedAmount2024-11-30 11072275core:RetainedEarningsAccumulatedLossescore:PreviouslyStatedAmount2023-11-30 11072275core:PreviouslyStatedAmount2024-11-30 11072275core:PreviouslyStatedAmount2023-11-30 11072275business:SmallEntities2023-12-012024-11-30 11072275business:Director12023-12-012024-11-30 11072275countries:EnglandWales2023-12-012024-11-30 11072275business:RegisteredOffice2023-12-012024-11-30 11072275core:PlantMachinery2023-12-012024-11-30 11072275core:FurnitureFittings2023-12-012024-11-30 11072275core:PlantMachinery2023-11-30 11072275core:FurnitureFittings2023-11-30 11072275core:PlantMachinery2024-11-30 11072275core:FurnitureFittings2024-11-30 110722752022-12-012023-11-30 iso4217:GBP xbrli:pure
Company Registration No. 11072275 (England and Wales)
MARVELLOUS PHARMA LTD Unaudited accounts for the year ended 30 November 2024
MARVELLOUS PHARMA LTD Unaudited accounts Contents
Page
- 2 -
MARVELLOUS PHARMA LTD Statement of financial position as at 30 November 2024
2024 
2023 
Notes
£ 
£ 
Fixed assets
Tangible assets
6,654 
8,317 
Current assets
Inventories
- 
4,719 
Debtors
31,853 
63,098 
Cash at bank and in hand
118,667 
48,533 
150,520 
116,350 
Creditors: amounts falling due within one year
(8,704)
2,891 
Net current assets
141,816 
119,241 
Total assets less current liabilities
148,470 
127,558 
Creditors: amounts falling due after more than one year
(197,500)
(200,000)
Net liabilities
(49,030)
(72,442)
Capital and reserves
Called up share capital
90 
90 
Profit and loss account
(49,120)
(72,532)
Shareholders' funds
(49,030)
(72,442)
For the year ending 30 November 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies. The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The director acknowledges his responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with the provisions of FRS 102 Section 1A - Small Entities. The profit and loss account has not been delivered to the Registrar of Companies.
The financial statements were approved by the Board and authorised for issue on 23 January 2025 and were signed on its behalf by
Mr Medhat Zaki Mahmoud Director Company Registration No. 11072275
- 3 -
MARVELLOUS PHARMA LTD Notes to the Accounts for the year ended 30 November 2024
1
Statutory information
MARVELLOUS PHARMA LTD is a private company, limited by shares, registered in England and Wales, registration number 11072275. The registered office is ABBEY GATE BUSINESS CENTER UNITE B HITCH, 35, LUTON, LU2 0ER, ENGLAND.
2
Compliance with accounting standards
The accounts have been prepared in accordance with the provisions of FRS 102 Section 1A Small Entities. There were no material departures from that standard.
3
Accounting policies
The principal accounting policies adopted in the preparation of the financial statements are set out below and have remained unchanged from the previous year, and also have been consistently applied within the same accounts.
Basis of preparation
The accounts have been prepared under the historical cost convention as modified by the revaluation of certain fixed assets.
Presentation currency
The accounts are presented in £ sterling.
Tangible fixed assets and depreciation
Tangible assets are included at cost less depreciation and impairment. Depreciation has been provided at the following rates in order to write off the assets over their estimated useful lives:
Plant & machinery
20%
Fixtures & fittings
20%
4
Tangible fixed assets
Plant & machinery 
Fixtures & fittings 
Total 
£ 
£ 
£ 
Cost or valuation
At cost 
At cost 
At 1 December 2023
10,508 
16,976 
27,484 
At 30 November 2024
10,508 
16,976 
27,484 
Depreciation
At 1 December 2023
6,649 
12,518 
19,167 
Charge for the year
771 
892 
1,663 
At 30 November 2024
7,420 
13,410 
20,830 
Net book value
At 30 November 2024
3,088 
3,566 
6,654 
At 30 November 2023
3,859 
4,458 
8,317 
5
Debtors
2024 
2023 
£ 
£ 
Amounts falling due within one year
VAT
- 
21,274 
Trade debtors
31,853 
41,824 
31,853 
63,098 
- 4 -
MARVELLOUS PHARMA LTD Notes to the Accounts for the year ended 30 November 2024
6
Creditors: amounts falling due within one year
2024 
2023 
£ 
£ 
VAT
2,174 
- 
Trade creditors
10,810 
- 
Taxes and social security
10,144 
9,756 
Loans from directors
(17,224)
(17,224)
Accruals
2,800 
2,800 
Deferred income
- 
1,777 
8,704 
(2,891)
7
Creditors: amounts falling due after more than one year
2024 
2023 
£ 
£ 
Loans from directors
197,500 
200,000 
8
Average number of employees
During the year the average number of employees was 4 (2023: 4).
- 5 -